MedTrace Logo

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

NCT00747539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2016-05-13

No results posted yet for this study

Summary

This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.

Conditions

Interventions

DRUG

Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)

Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.

Sponsors & Collaborators

Principal Investigators

  • Charles H. Hinkin, PhD · University of California, Los Angeles

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747539 on ClinicalTrials.gov